Showing 1901-1910 of 2123 results for "".
- Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosishttps://practicalneurology.com/news/intranasal-foralumab-provides-neuroimaging-and-clinical-improvements-in-secondary-progressive-multiple-sclerosis/2469929/In the expanded access program, after 3 months of intranasal foralumab (Tiziana Life Sciences, New York, NY) treatment of secondary progressive multiple sclerosis (SPMS), a second participant showed clinical improvement on Positron Emission Tomography (PET) imaging analysis, neurologic exami
- Risdiplam Treatment of Type 1 Spinal Muscular Atrophy in Infants Has Long-Term Benefithttps://practicalneurology.com/news/risdiplam-treatement-of-type-1-spinal-muscular-atrophy-in-infants-has-long-term-benefit/2469904/New 3-year data from the FIREFISH study (NCT02913482) reinforce long-term efficacy and safety of risdiplam (Evrysdi; Genentech, South San Francisco, CA) for treatment of symptomatic type 1 spinal muscular atrophy (SMA) in infancy. Appr
- Increase in Antioxidants Correlated With Reduced Risk of Dementiahttps://practicalneurology.com/news/increase-in-antioxidants-correlated-with-reduced-risk-of-dementia/2469902/A study found individuals with high levels of the antioxidants lutein, zeaxanthin, and beta-cryptoxanthin in blood were less likely to develop dementia 16 years later compared with people with lower levels. Study participants had antioxidant blood levels measured and were then eva
- Artificial intelligence Digital Pathology Able to Detect Early-Stage Parkinson Diseasehttps://practicalneurology.com/news/artificial-intelligence-digital-pathology-able-to-detect-early-stage-parkinson-disease/2469891/A new artificial intelligence (AI)-enabled digital pathology technology (Morphology Feature Array; PreciseDx, New York, NY) can diagnose Parkinson disease (PD) accurately in individuals before onset of severe symptoms. Using image patches from biopsy samples, the algorithm had 99% sensi
- Phase 2b Trial of Bryostatin-1 for Alzheimer Disease Completes Enrollmenthttps://practicalneurology.com/news/phase-2b-trial-of-bryostatin-1-for-alzheimer-disease-completes-enrollment/2469890/The phase 2b clinical trial (NCT04538066) of bryostatin-1 (Synaptogenix, New York, NY) for individuals with advanced and moderately severe Alzheimer disease (AD) has completed enrollment with 100
- Long-Term Efficacy and Safety of Ganaxolone for Treatment of Cyclin-Dependent Kinase-Like 5 Deficiency Disorder—A Developmental Encephalopathic Epilepsyhttps://practicalneurology.com/news/long-term-efficacy-and-safety-of-ganaxolone-for-treatment-of-cyclin-dependent-kinase-like-5-deficiency-disorder-a-developmental-encephalopathic-epilepsy/2469875/Ganaxolone (Ztalmy; Marinus Pharmaceuticals, Radnor, PA) was recently approved for adjunctive treatment of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in people, age 2 years or more. CDD, which can be diagnosed with a genetic test, is among the developmental
- Continuous Subcutaneous Infusion of Levodopa/Carbidopa Has Long-Term Safety in Parkinson Diseasehttps://practicalneurology.com/news/contours-subcutaneous-infusion-of-levodopacarbidopa-has-long-term-safety-in-parkinson-disease/2469868/The phase 2b BeyoND study demonstrates the infusion of levodopa/carbidopa (ND0612; Neuroderm, Israel) was safe and well tolerated over a year long period in individuals with Parkinson disease (PD) with motor fluctuations. As reported in 2021, treatment with continuous subcutaneous infusion of lev
- Ecopipam Reduced Tic Severity in Tourette Syndromehttps://practicalneurology.com/news/ecopipam-reduced-tic-severity-in-tourette-syndrome/2469866/In a clinical trial (NCT04007991) of ecopipam, children and teens (age 6 to 17 years) with Tourette syndrome who were treated with ecopipam for 3 months had improved scores on tests of tic severity after 3 months. Among those who were
- Brain-Computer Interface, Implanted Endovascularly, Allows People With Paralysis to Operate Computers With Their Thoughtshttps://practicalneurology.com/news/brain-computer-interface-implanted-endovascularly-allows-people-with-paralysis-to-operate-computers-with-their-thoughts/2469862/In a first-in-human study, 4 participants were implanted with a brain-computer interface (BCI) (Stentrode, Synchron, Brooklyn, NY) delivered via an endovascular stent to the superior sagittal sinus. The brain-computer interface allowed participants with paralysis to independently perform computer
- FDA Approves Expanded Indication of Fenfluramine for Lennox-Gastaut Syndromehttps://practicalneurology.com/news/fda-approves-expanded-indication-of-fenfluramine-for-lennox-gastaut-syndrome/2469861/The Food and Drug Administration (FDA) approved an expanded indication of fenfluramine (Fintepla; Zogenix, Emeryville, CA) to treat seizures in Lennox-Gastaut syndrome (LGS) in individuals age 2 years or more. “The approval of Fintepla for Lennox-Gastaut syndrome highlights our co